Innovative miR-29 Antagonists for Aortic Aneurysm Treatment
The present invention relates to the use of antagonists of the miR-29 family to prevent and/or treat aortic aneurysms and rupture of atherosclerotic plaques.
Further Information: PDF
INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
Phone: +49 (0)69/2561632-0
Contact
Dr. Otmar Schöller
